Novel Kv1.3 blockers for immunosuppression: WO2012155199

被引：2
|
作者：
William Nguyen [1 ]
机构：
[1] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2013年 / 23卷 / 11期
关键词：
autoimmune disorder; Kv1.3; MS; potassium channel; psoriasis; rheumatoid arthritis; GATED POTASSIUM CHANNEL; MEMORY T-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; ION-CHANNEL; K+ CHANNELS; DERIVATIVES; IMMUNOMODULATION; KHELLINONE; ACTIVATION;
D O I：
10.1517/13543776.2013.831072
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A recent patent application from Bionomics/Merck Serono describes novel compounds as blockers of the voltage-gated Kv1.3 ion channel. The blockade of this channel shows great promise as a new therapeutic target for the treatment of autoimmune disorders such as multiple sclerosis, psoriasis, diabetes and rheumatoid arthritis. The generic claim of this patent refers to a new chemotype of Kv1.3 blockers based on an amide core with potent IC50's which are potentially within the nanomolar range. This article briefly reviews the chemistry and biology found in the patent and compares it with previous discoveries in the field.
引用
收藏
页码：1511 / 1516
页数：6
相关论文
共 50 条
  • [1] Novel Kv1.3 blockers for the treatment of autoimmune diseases
    Kudryashova, K.
    Kuzmenkov, A.
    Nekrasova, O.
    Feofanov, A.
    Grishin, E.
    Vassilevski, A.
    FEBS JOURNAL, 2014, 281 : 149 - 149
  • [2] Kv1.3 blockers for treatment of autoimmune diseases
    Tasler, Stefan
    Dreker, Tobias
    Kraus, Juergen
    Hamm, Svetlana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [3] Human T-cell Kv1.3 potassium channel blockers: new strategies for immunosuppression
    Lew, A
    Chamberlin, AR
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (06) : 905 - 915
  • [4] Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840
    Wulff, Heike
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (12) : 1759 - 1765
  • [5] Use of Kv1.3 Blockers for Inflammatory Skin Conditions
    Nguyen, W.
    Howard, B. L.
    Neale, D. S.
    Thompson, P. E.
    White, P. J.
    Wulff, H.
    Manallack, D. T.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (26) : 2882 - 2896
  • [6] Benzamide derivatives as blockers of Kv1.3 ion channel
    Miao, SW
    Bao, JM
    Garcia, ML
    Goulet, JL
    Hong, XF
    Kaczorowski, GJ
    Kayser, F
    Koo, GC
    Kotliar, A
    Schmalhofer, WA
    Shah, K
    Sinclair, PJ
    Slaughter, RS
    Springer, MS
    Staruch, MJ
    Tsou, NN
    Wong, F
    Parsons, WH
    Rupprecht, KM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (06) : 1161 - 1164
  • [7] Scorpion toxins targeting Kv1.3 channels: insights into immunosuppression
    Oliveira, Isadora S.
    Ferreira, Isabela G.
    Alexandre-Silva, Gabriel M.
    Cerni, Felipe A.
    Cremonez, Caroline M.
    Arantes, Eliane C.
    Zottich, Umberto
    Pucca, Manuela B.
    JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES, 2019, 25
  • [8] Design, synthesis, and testing of Kv1.3 blockers based on diphenoxylate
    Nguyen, William
    Wulff, Heike
    Howard, Brittany
    White, Paul
    Thompson, Philip
    Manallack, David
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [9] Targeting effector memory T-cells with Kv1.3 blockers
    Wulff, Heike
    Pennington, Michael
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2007, 10 (04) : 438 - 445
  • [10] A Novel Role for Kv1.3 Blockers: Protecting Neural Progenitor Cells from a Hostile Inflammatory Environment
    Peng, Haiyan
    Huss, David J.
    JOURNAL OF NEUROSCIENCE, 2010, 30 (32): : 10609 - 10611
12345